Strategic divestiture Recent asset sale to Esteve Huayi and planned expansion via Infusion Specialty Therapies indicate portfolio realignment and a broader U.S. footprint. This creates opportunities to engage with infusion-focused providers and payers, explore partnerships or distribution arrangements around infusion therapies, and offer complementary manufacturing, packaging, or services to hospitals and ambulatory centers adapting to the new structure.

Infusion therapy focus TerSera's emphasis on oncology, acute care and non-opioid pain management aligns with rising demand for infusion-based therapies in hospital and outpatient settings. Target cancer centers, infusion clinics, and IDNs with non-opioid pain care programs and offer optimized supply, fast access, and flexible manufacturing/packaging capabilities.

Culture advantage Strong employee engagement and multiple workplace awards suggest a stable, motivated field team and collaborative partner network. Leverage employer branding to recruit top clinical and sales talent for tumor boards, payer negotiations, and patient support programs; also a potential differentiator when engaging with hospital systems.

Digital readiness Use of Veeva CRM and HIPAA compliance indicates readiness for regulated provider engagement and patient data handling. Could enable scalable, compliant outreach to oncologists, infusion centers, and payers, plus data-driven marketing and potential EHR integrations or clinical trial operations.

Partnership history Historical collaborations with AstraZeneca and TESARO show TerSera's openness to co-development and commercialization deals. This track record suggests BD opportunities for licensing, co-promotion, or buy-in partnerships with pharma players seeking infusion-ready assets or non-opioid pain therapies.